Regional Insights into the Relationship Between Metabolic Associated Steatotic Liver Disease and Chronic Kidney Disease: a Socioeconomic Perspective on Disease Correlation

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2025 Mar 14

PMID 40082841

Authors

Jiang Bai

Lijuan Zhang

Mingyan Zhang

Yifan Hao

Zhen Yi

Yun Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Studies exploring the correlation between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and the increased risk of chronic kidney disease (CKD) from a country-specific perspective have been limited. This study addresses regional variations and the role of the Socio-Demographic Index (SDI) in this relationship.

Methods: This analysis integrates MASLD and country-level CKD data from the Global Burden of Disease study 2021. To evaluate the relationships between MASLD and CKD incidence, mixed-effects linear regression models that account for country-level random effects were employed. This analysis was adjusted for median age, percentage of males, SDI, and metabolic risk factors.

Results: The incidence of MASLD and CKD demonstrated a similar regional distribution, with the highest of MASLD and CKD occurring in North Africa and the Middle East. After adjusting for age, gender, systolic blood pressure, fasting plasma glucose, body mass index, and SDI, a higher incidence of MASLD was associated with an increased incidence of CKD (p < 0.001), with MASLD incidence accounting for 53.0% of the explained variance in CKD incidence. Additionally, SDI, demographic variables (median age, population of male) and metabolic risks (High SBP, FPG and BMI), were responsible for 10.4%, 6.3%, and 30.3% of the explained variance in CKD incidence, respectively. Different patterns emerged in this association according to SDI status. In low SDI countries, significant associations were observed between increasing MASLD incidence rates and higher CKD incidence (p = 0.007), whereas in high SDI countries, no significant associations were found between MASLD and CKD incidence (p = 0.106).

Conclusions: Our findings reveal a geographical correlation between MASLD and CKD incidence, contingent upon socioeconomic factors. To effectively mitigate the global burden of MASLD and CKD, it is imperative to design and implement targeted public health strategies that consider the unique socioeconomic contexts of each region, thus fostering equitable health outcomes.

References

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

Younossi Z, Zelber-Sagi S, Kuglemas C, Lazarus J, Paik A, de Avila L . Association of food insecurity with MASLD prevalence and liver-related mortality. J Hepatol. 2024; 82(2):203-210. DOI: 10.1016/j.jhep.2024.08.011. View

Chesnaye N, Ortiz A, Zoccali C, Stel V, Jager K . The impact of population ageing on the burden of chronic kidney disease. Nat Rev Nephrol. 2024; 20(9):569-585. DOI: 10.1038/s41581-024-00863-9. View

Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y . Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism. 2024; 158:155958. DOI: 10.1016/j.metabol.2024.155958. View

Ying M, Shao X, Qin H, Yin P, Lin Y, Wu J . Disease Burden and Epidemiological Trends of Chronic Kidney Disease at the Global, Regional, National Levels from 1990 to 2019. Nephron. 2023; 148(2):113-123. PMC: 10860888. DOI: 10.1159/000534071. View

Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A . Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016; 4(5):e307-19. DOI: 10.1016/S2214-109X(16)00071-1. View

Xie Y, Bowe B, Mokdad A, Xian H, Yan Y, Li T . Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018; 94(3):567-581. DOI: 10.1016/j.kint.2018.04.011. View

Lazarus J, Mark H, Villota-Rivas M, Palayew A, Carrieri P, Colombo M . The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. J Hepatol. 2021; 76(4):771-780. DOI: 10.1016/j.jhep.2021.10.025. View

Diaz L, Fuentes-Lopez E, Ayares G, Idalsoaga F, Arnold J, Marquez-Lomas A . The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol Hepatol. 2022; 7(6):552-559. DOI: 10.1016/S2468-1253(22)00008-5. View

10.

Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg J . Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2020; 71(1):156-162. DOI: 10.1136/gutjnl-2020-323082. View

11.

Byrne C, Targher G . NAFLD as a driver of chronic kidney disease. J Hepatol. 2020; 72(4):785-801. DOI: 10.1016/j.jhep.2020.01.013. View

12.

Kwon S, Park J, Park S, Lee Y, Kim G, Hur K . MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci Rep. 2023; 13(1):1796. PMC: 9889784. DOI: 10.1038/s41598-023-27762-6. View

13.

Maleki Z, Hassanzadeh J, Ghaem H . Correlation between socioeconomic indices and epidemiological indices of thyroid cancer from 1990 to 2019 year: a global ecologic study. BMC Cancer. 2024; 24(1):467. PMC: 11017482. DOI: 10.1186/s12885-024-12176-y. View

14.

Zhang H, Zhou X, Shapiro M, Lip G, Tilg H, Valenti L . Global burden of metabolic diseases, 1990-2021. Metabolism. 2024; 160:155999. DOI: 10.1016/j.metabol.2024.155999. View

15.

Al Taani O, Aleyadeh W, Al-Ajlouni Y, Alnimer L, Ismail A, Natour B . The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades. BMC Public Health. 2024; 24(1):2979. PMC: 11514855. DOI: 10.1186/s12889-024-20445-5. View

16.

Harrison X, Donaldson L, Correa-Cano M, Evans J, Fisher D, Goodwin C . A brief introduction to mixed effects modelling and multi-model inference in ecology. PeerJ. 2018; 6:e4794. PMC: 5970551. DOI: 10.7717/peerj.4794. View

17.

Chonco L, Landete-Castillejos T, Serrano-Heras G, Serrano M, Perez-Barberia F, Gonzalez-Armesto C . Anti-tumour activity of deer growing antlers and its potential applications in the treatment of malignant gliomas. Sci Rep. 2021; 11(1):42. PMC: 7794318. DOI: 10.1038/s41598-020-79779-w. View

18.

Vollset S, Goren E, Yuan C, Cao J, Smith A, Hsiao T . Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. Lancet. 2020; 396(10258):1285-1306. PMC: 7561721. DOI: 10.1016/S0140-6736(20)30677-2. View

19.

ODonnell O, ONeill S, Van Ourti T, Walsh B . conindex: Estimation of concentration indices. Stata J. 2016; 16(1):112-138. PMC: 4819995. View

20.

Handelsman Y, Butler J, Bakris G, DeFronzo R, Fonarow G, Green J . Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023; 37(2):108389. DOI: 10.1016/j.jdiacomp.2022.108389. View